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Abstract
The epithelial proliferations that are designated adenoid basal carcinoma (ABC) in the current
classification from the World Health Organization represent <1% of all cervical malignancies. These
lesions may be associated, and occasionally show morphologic transitions with, conventional
cervical malignancies. The determination of the precise frequency with which these so-called ABCs
show this association is hampered by the inherent selection bias in the reported cases. However,
this frequency appears to be substantial (>15%). The biologic course of ABCs that are associated
with separate malignancies is largely dependent on the clinicopathologic parameters of the
associated malignancies. Morphologically pure lesions, in contrast, have largely been associated with
favorable patient outcomes, as none of the 66 reported patients have experienced tumor
recurrence, metastases or tumor-associated death, irrespective of the modality of treatment.
Although the finding of genome integrated high-risk human papillomavirus (HPV) types and p53
alterations in adenoid basal lesions (ABL) argue in support of their neoplastic nature, we identified
no lines evidence that suggest an inherent malignancy for morphologically pure lesions. The finding
of morphologic transitions between ABLs and conventional malignancies and shared HPV types in
these areas, suggest that ABLs have some malignant potential. However, the precise magnitude of
this potential is not readily quantifiable and should not dictate the management of morphologically
pure lesions that are entirely evaluable. ABLs continue to occupy a unique position in human
oncology in which the term carcinoma (without an in-situ suffix) is applied to a tumor that has not
been shown to recur, metastasize or cause death. We concur with a previous proposal that the
term ABC should be discarded and replaced with Adenoid Basal Epithelioma (ABE). In our opinion,
there is insufficient evidence at present time to expose patients with morphologically pure lesions
to the ominous implications – social, psychological, medical, financial – of a "carcinoma" diagnosis.
Morphologically impure lesions should not be designated ABC or ABE. Furthermore, given the
uncertainties regarding the frequency with which ABE are associated with separate malignancies,
we suggest that the ABE designation only be applied when the tumor in question is entirely
evaluable e.g in a hysterectomy specimen or in an excisional biopsy with negative margins.
Otherwise, the generic designation Adenoid Basal Tumor is preferable. This approach strikes an
appropriate balance between the need to prevent over-treatment of pure lesions on one hand, and
the need to ensure that the lesions are indeed pure on the other.
Published: 15 August 2006
Diagnostic Pathology 2006, 1:18 doi:10.1186/1746-1596-1-18
Received: 25 July 2006
Accepted: 15 August 2006
This article is available from: http://www.diagnosticpathology.org/content/1/1/18
© 2006 Russell and Fadare; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Diagnostic Pathology 2006, 1:18 http://www.diagnosticpathology.org/content/1/1/18
Page 2 of 14
(page number not for citation purposes)
Background
The historical evolution of the lesions that are currently
designated "adenoid basal carcinomas" [1-25] is inextrica-
bly linked to adenoid cystic carcinoma [26-84], a diagnos-
tic entity under which it was subsumed for many years
prior to and even after its delineation, and a tumor with
which it shares some morphologic features and probably,
a histogenetic basis. Adenoid cystic carcinoma of the cer-
vix (ACC) was originally described as "cylindroma" by
Paalman and Counsellor [84] in 1949. Fifteen years later,
Moss and Collins [83] described a distinctive cervical neo-
plasm that was predominantly comprised of ACC but
which also contained foci of small basaloid nests. The
authors designated this tumor "adenoid cystic basal carci-
noma". However, the 1966 report of Baggish and Wood-
ruff [24], in which the term "adenoid-basal carcinoma"
(ABC) was initially used, is widely credited [85-89] with
the delineation of this lesion as a separate clinicopatho-
logic entity. The latter authors described 3 examples of a
morphologically distinctive cervical tumor that was com-
prised of small basaloid cells nests that seemed to be
"dropping off" the basal layer of the overlying surface epi-
thelium, which did not elicit any significant stromal reac-
tion, and which in all 3 cases, were associated with
carcinoma-in-situ of the overlying epithelium. All 3
patients were treated with surgical resections and none
had experienced recurrences within the follow-up period.
Based in part on the absence of a significant stromal reac-
tion, the authors suggested that the lesions were "only as
locally invasive as the basal cell lesion of the skin and
demand no more radical therapy than wide local exci-
sion" [24]. In a follow-up report [23], all 3 patients were
alive and well 5–13 years after their hysterectomies. In the
same report, Baggish and Woodruff reported 5 additional
cases, introducing the term "adenoid basal hyperplasia"
[23] as well as the concept that different malignancies
may be associated with ABC. In 1972, Shilkin [73]
reported a cervical tumor which he designated ABC. The
author's photomicrographs showed, in our opinion, an
archetypal example of ACC. However, a histochemical
analysis of the lesion showed it to be devoid of myoepi-
thelial cells, in contrast to ACCs elsewhere. Thus, the
author did not consider the lesion an example of ACC and
designated the lesion an ABC. The ABC/ACC distinction
continued to be very nebulous in the middle to late
1970s. The 1975 report of Russell [22] suggested that the
author considered the terms to be interchangeable. In the
1980 series of ACC reported by Prempree et al [58], clear
examples of ABC are included, and at least one case of
ABC (case 3) is included in the series of cervical "basaloid
carcinoma" reported by Daroca and Dhurandhar [25] that
same year. It was not until the publication of two impor-
tant reports in 1985 [21] and 1988 [20] that the important
clinicopathologic differences between ACC and ABC were
clarified. Subsequent reports have thus been able to focus
attention on the many important aspects of true ABC that
remain to be understood, including histogenesis, precise
malignant potential, and other areas that are still lacking
in consensus, including nomenclature. In this review, the
descriptive term adenoid basal lesion(s) (ABL) is used to
generically refer to the full spectrum of adenoid basal
lesions that that have been variably described in the liter-
ature as adenoid basal hyperplasia, ABC (pure lesions and
those associated with separate malignancies) and adenoid
basal epithelioma, unless otherwise specified. A compre-
hensive clinicopathologic review of all reported cases of
ABL in the english-language literature is presented, and we
discuss our practical approach to these enigmatic lesions.
Incidence
There are no studies that have systematically investigated
the incidence of ABL. However, retrospective analyses by
most authors suggest that pure ABL constitute less than
1% of all cervical malignancies [85]. Teramoto et al [2]
identified 1 pure ABL out of 2600 "resected cervical malig-
nancies" diagnosed at the Shikoku Cancer Center (Japan).
In contrast, a study emanating out of Women's Center in
Australia identified 5 cases out of 106 (4.7%) cervical can-
cers diagnosed over a 25–26-month period [17]. A search
of the computerized database of a large academic medical
center in Northeast United States yielded only 4 cases
coded as adenoid basal out of 189 cervical carcinomas diag-
nosed over a 7-year period (O Fadare, unpublished data,
February 2005).
Clinical features of patients with pure adenoid basal lesions
The 66 previously reported morphologically pure ABL in
the English literature are summarized in table 1. Cases
associated with "separate malignancies" (vide infra) have
been excluded. However, we elected to keep 3 cases with
microinvasive carcinoma, because the latter only develops
in the setting of high grade dysplasia – a nearly ubiquitous
finding in these patients – and because their presence is
not expected to alter the natural history of the ABL any
more than the high grade dysplasia alone. For the 52
patients in which this information was itemized, patient
age ranged from 21 to 91 years (mean 64.6; Median 66.5).
Although some of the earlier series [23,24] as well as those
emanating out of South Africa [7,9] seemed to suggest a
marked predilection for black females, others have found
no such predilection [20,21]. However, ABL does seem to
disproportionately affect non-white women. Approxi-
mately 80% of patients were asymptomatic at initial diag-
nosis, and 80–90% of them came to clinical attention due
to an abnormal pap smear; the latter was a high-grade
squamous intraepithelial lesion in >90% of cases. A pelvic
examination fails to reveal an abnormality in almost all
cases of pure ABL. Similarly, pathologic evaluation of the
hysterectomy or conization specimens usually fails to
reveal a mass lesion. Cervical ulceration, hemorrhage orD
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) Table 1: Previously reported cases of morphologically pure adenoid basal lesions in the English literature.
Authors (reference) No of 
patients
age (yrs) Race Presentation/pap 
smear findings
Gross or pelvic 
examination 
findings
Associated 
cervical 
intraepithelial 
dysplastic 
lesion
Diagnostic and/or 
Therapeutic measure(s)
Lymph 
node 
status
Follow-
up, 
(months)
1 Baggish & Woodruff [24]*** 1 63 white Vaginal bleeding/NR Atrophic vaginal 
mucosa; NCF
CIS Hysterectomy/BSO NPR NED 156
2 1 62 black Uterine prolapse/NR NCF CIS Hysterectomy NPR NED 84
3 1 39 black Abnormal pap smear NR CIS Conization/Hysterectomy NPR NED 60
4 Baggish & Woodruff [23] 1 60 white "incidental"/negative NCF None Hysterectomy/BSO NPR NED 6
5 Cases 1–3 1 80 white "incidental"/negative NCF None Hysterectomy/BSO NPR NED 6
6 1 80 black Lower abdominal 
pressure/negative
Cervical eversion CIS Conization/Hysterectomy/BSO NPR NED 6
7 Russell & Laverty [22] 1 62 NR uterine prolapse and 
vaginal bleeding/"Very 
Atypical cells"
Cervical ulceration None Hysterectomy NPR NR
8 Daroca & Dhurandhar [25], Case 3 1 60 NR Post menopausal bleeding Cervical erosion CIS Hysterectomy/BSO NPR NED 12
9–13 van Dinh & Woodrhuff [21]## 5 mean 56 white 
3, 
black 
2
Vaginal bleeding n = 1, 
asymptomatic n = 4/
moderate atypia n = 5
Cervical ulceration 
n = 1, NCF n = 4
CIN3 n = 3, 
None n = 2
dilatation and curettage n = 1, 
Hysterectomy +/- BSO n = 4
NPR DOC n = 
1, NED 
24–144, n 
= 4
14 Ferry & Scully [20] 1 69 black Abnormal pap smear n = 
11, PMB n = 2
NCF n = 10, 
cervical induration 
n = 2,
CIS Hysterectomy/BSO NPR NED 60
15 Cases 1–13 1 63 NR CIS Hysterectomy/BSO NPR NED 120
16 1 66 black CIS Cervical excision/Rad NPR DOC 24
17 1 75 white CIS Hysterectomy/BSO NPR NED 84
18 1 65 asian CIS Hysterectomy/BSO/Rad NPR NED 72
19 1 51 NR CIS Hysterectomy/BSO NPR NED 24
20 1 56 NR CIS Cervical excision NPR NED 72
21 1 78 white CIS Cervical excision NPR NED 72
22 1 59 white CIS Hysterectomy/RSO NPR NED 60
23 1 67 black CIS Hysterectomy/BSO NPR NED 48
24 1 57 white CIS Hysterectomy/BSO NPR NED 24
25 1 72 black CIS Conization NPR NED 29
26 1 57 NR CIS NR NPR DOC 0
27 Langlois et al [19] 1 59 NR Asymptomatic/abnormal 
pap smear
NCF CIN3 Conization, Hysterectomy NPR NR
28 Peterson & Neumann [18] 1 64 other Asymptomatic/HGSIL NR CIN2 Conization NPR NR
29 Layton-Henry et al [17] 1 62 NR Abnormal Pap smear n = 
5/HGSIL, one with 
"possible invasion", n = 3; 
inconclusive n = 2
NCF CIN Conization, Hysterectomy, BSO, 
LN
Negativ
e
NED 1
30 1 64 NR NCF CIN Conization, Hysterectomy, BSO NPR NED 7
31 1 75 NR NCF CIN Conization NPR NED 15
32 1 60 NR NCF CIN Conization, Hysterectomy, BSO, 
LN
Negativ
e
NED 26
33 1 59 NR NCF CIN Conization, Hysterectomy, BSO, 
LN
Negativ
e
VAIN 16D
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) 34 Powers & Frable [16] 1 79 white Asymptomatic/SCC AWL CIS Conization, Hysterectomy BSO, 
LN
Negativ
e
NED 18
35 1 67 black Presentation @/"severely 
atypical small cells"
NCF None Conization, Rad NPR NED 16
36–
40
Jones et al [13] 1 Mean 51 white 
n = 5
abnormal pap n = 4, PMB 
n = 1
"Ulcerated, 
irregular indurated 
mass" n = 2, NCF n 
= 3
CIN 1 to3 (n = 
5)
Hysterectomy/BSO (n = 5), 
Hysterectomy/BSO/LN (n = 4). 
One patient also received Rad
Negativ
e
NED 26 
Mean
41 Yoshida et al [14] 1 49 asian Asymptomatic NCF CIN 3 Hysterectomy NPR NR
42–
45*
Grayson et al [9] (Cases 4,5,7,8) 4 NI black NI NI NI NI NI NI
46 Brainard & Hart [10] 1 91 NR Dysuria, Night sweats/
HGSIL
Focal hemorrhage CIS Conization NPR NED 4
47 1 68 NR Asymptomatic/HGSIL NCF CIS Conization, Hysterectomy, BSO, 
LN
Negativ
e
NED 5
48 1 78 NR Vaginal spotting/HGSIL NCF Severe dysplasia Conization, Hysterectomy, BSO, 
LN
Negativ
e
NED 15
49 1 30 NR Asymptomatic/HGSIL NCF Moderate 
severe dysplasia
Conization, Hysterectomy, BSO, 
LN
Negativ
e
NED 17
50 1 71 NR Asymptomatic/HGSIL NCF CIS Conization NPR NED 21
51 1 67 NR Asymptomatic/HGSIL NCF Microinvasive 
Carcinoma##
Conization, Hysterectomy, BSO, 
LN
Negativ
e
NED 28
52 1 70 NR Dysuria, Hematuria/
Negative
NCF None Hysterectomy NPR NED 30
53 1 72 NR Asymptomatic/HGSIL NCF CIS Conization, Hysterectomy NPR NED 70
54 1 71 NR Asymptomatic/HGSIL NCF CIS Conization, BSO, Rad, LN Negativ
e
NED 82
55 1 76 NR NR/HGSIL NCF CIS Hysterectomy, BSO NPR NED 24
56 1 70 NR Asymptomatic/LGSIL NCF CIS Hysterectomy, Rad NPR NED 63
57 1 83 NR Asymptomatic/HGSIL NCF CIS Conization NPR NED 87
58 1 35 NR Pelvic mass@/Normal NCF None Hysterectomy, BSO, LN, 
Chemotherapy [all@]
Negativ
e
NED 49
59 1 57 NR Asymptomatic/CIS NCF CIN Conization NPR NED 5
60 1 69 NR Asymptomatic/abnormal 
pap smear
NCF None Conization NPR NR
61 Senzaki et al [11] 1 69 asian Vaginal bleeding NCF CIS Hysterectomy, BSO, LN [all@] Negativ
e
NED 6
62 Hiroi et al [6] 1 74 asian Vaginal bleeding NCF CIN 3 Hysterectomy NPR NR
63 Khoury et al [4] 1 79 black Asymptomatic/HGSIL NCF Severe dysplasia Hysterectomy, BSO NPR NR
64 Teramoto [2] 1 69 asian Asymptomatic/HGSIL NR CIN3 Hysterectomy and 
chemotherapy@
NPR 108
65 Zamecnik & Skrivanek [1] 1 21 NR Asymptomatic//LGSIL NCF CIN1-3 Conization NPR NED 1
66 Parwani et al [1] 1 65 NR NR/HGSIL NR Microinvasive 
Carcinoma##
Conization, Hysterectomy, LN Negativ
e
NED 78
Abbreviations: NED, no evidence of disease; CIS, carcinoma in situ; LN, lymph node dissection; N/A, not applicable; PMB postmenopausal bleeding; BSO or RSO bilateral or right salpingo-oophorectomy; Rad, 
radiation therapy; NPR Lymph node dissection not performed or reported; NCF no gross cervical findings; DOC death from other causes; LGSIL low grade squamous intraepithelial lesion; HGSIL high grade 
squamous intraepithelial lesion; CIN cervical intraepithelial neoplasia. Cases in Cviko et al [8] are excluded due to lack of sufficient clincopathological information; SCC squamous cell carcinoma. **Presumes 
cases in Grayson et al (1997) are the same in Grayson et al (1999); AWL: acetowhite lesions. NI: information not included due to a lack of sufficient itemization in original manuscript. NA: information not 
available. *excludes the 4 cases in Grayson et al [9] with "divergent neoplastic epithelial differentiation"; *** follow-up as reported in [23]; @ Unrelated to cervical pathology; ## Includes the cases of 
microinvasive carcinoma [1,10,20], see text
Table 1: Previously reported cases of morphologically pure adenoid basal lesions in the English literature. (Continued)Diagnostic Pathology 2006, 1:18 http://www.diagnosticpathology.org/content/1/1/18
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eversion was identified in 7 cases, and a mass lesion was
noted in 2 [13].
Pathologic features of pure adenoid basal lesions
Morphologically pure ABL are not macroscopically evi-
dent. As previously noted, >90% of cases have an associ-
ated high-grade squamous intraepithelial lesion. In the
subepithelial compartment is typically the incidentally
discovered epithelial proliferation of ABL. The latter is
comprised of multiple, small nests of basaloid epithelial
cells. Scanning magnification often reveals an apparently
deeply invasive process (figure 1); nests extended down
into the stroma for distances that ranged from 2 mm to 10
mm (mean 4.3 mm) in one study [10] and invaded to 50–
90% of the cervical stroma in another [13]. Based in part
on the depth of invasion, 6 (46%) of 13 and 7 (54%) of
13 cases were International Federation of Gynecology and
Obstetrics stage 1A and 1B respectively in one study [20].
Extensions into the myometrium of the isthmus have also
been reported [17]. The nests are often arranged in a vague
lobule-like configuration [10]. Each nest is comprised of
monomorphic, small cells with basaloid, round to oval
nuclei, inconspicuous nucleoli and scant cytoplasms (fig-
ure 2 and 3). Rare examples may show prominent clear
cell change [9] (figure 4). The cells often palisade around
the peripheral zones of the nests, in a pattern reminiscent
of cutaneous basal cell carcinoma [20]. The nests are most
commonly small (<100 cells) and solid, but may form
glandular or even cribriform structures (figure 5). The lat-
ter were lined by cells with ciliary structures suggestive of
tuboendometrioid differentiation in one case [1]. In sup-
port of their true glandular nature, another case was found
to be mucicarcmine positive in these foci [14]. Secretory
material may occasionally be identified within the lumen
of the glandular structures (figure 6). Small basement
membrane-like material may also be occasionally
encountered (figure 7). Foci of squamous metaplasia may
involve nests of ABL (figure 8), and such metaplasia may
be so extensive as to cause the lesion to simulate an inva-
sive squamous cell carcinoma (SCC). This potential pitfall
is further magnified because the metaplastic nests are typ-
ically expanded and may contain cells showing atypia. In
High power view of adenoid basal nests, each comprised of  monomorphic, small cells with basaloid, round to oval nuclei,  inconspicuous nucleoli and scant cytoplasms (hematoxylin  and eosin, original magnification 60×) Figure 3
High power view of adenoid basal nests, each comprised of 
monomorphic, small cells with basaloid, round to oval nuclei, 
inconspicuous nucleoli and scant cytoplasms (hematoxylin 
and eosin, original magnification 60×).
Scanning magnification view of a pure adenoid basal lesion  (adenoid basal epithelioma), showing an infiltrative prolifera- tion of basaloid nests Figure 1
Scanning magnification view of a pure adenoid basal lesion 
(adenoid basal epithelioma), showing an infiltrative prolifera-
tion of basaloid nests. (hematoxylin and eosin, original magni-
fication 10×)
Intermediate power view of adenoid basal nests Figure 2
Intermediate power view of adenoid basal nests. Note the 
lack of any significant stromal reaction. (hematoxylin and 
eosin, original magnification 20×)Diagnostic Pathology 2006, 1:18 http://www.diagnosticpathology.org/content/1/1/18
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our experience, all cases showing this pattern have been
involved by low-grade dysplasia and transitions from
clefts with more clearly diagnostic foci were evident.
Other authors [10] have noted that these nests typically
have a faint, CAM 5.2 immunopositive rim of basaloid
cells at their peripheries. These squamous nests may show
prominent microcyst formation [4,13].
In their seminal study, Baggish and Woodruff emphasized
that the nests immediately subjacent to the overlying epi-
thelium seemed to be "dropping off" from it and were
"well-demarcated from the adjacent stroma" [24]. Those
authors have also emphasized the absence of any signifi-
cant stromal reaction to the nests (figure 2), in contrast to
the stromal hyalinization that may be seen in ACC. Brain-
ard and Hart [10], however, noted that in 50% of their 12
cases, foci of "stroma edema or loosening" were present
around the ABL nests and a small lymphoplasmacytic
infiltrate was present around the nests in all 12 cases.
Small basement membrane-like material may be present in  adenoid basal lesions Figure 7
Small basement membrane-like material may be present in 
adenoid basal lesions. (hematoxylin and eosin, original magni-
fication 40×)
Small glandular or acinar structures such as is illustrated are  not uncommonly found in adenoid basal lesions Figure 5
Small glandular or acinar structures such as is illustrated are 
not uncommonly found in adenoid basal lesions. (hematoxy-
lin and eosin, original magnification 60×)
Some adenoid basal nests may show prominent clear cell  change due to accumulation of cytoplasmic glycogen in con- stituent cells Figure 4
Some adenoid basal nests may show prominent clear cell 
change due to accumulation of cytoplasmic glycogen in con-
stituent cells. Basaloid cells are still evident at the periphery 
of this nest (lower field). (hematoxylin and eosin, original 
magnification 60×)
The luminal compartments of the gland-like structures may  contain secretory material Figure 6
The luminal compartments of the gland-like structures may 
contain secretory material. (hematoxylin and eosin, original 
magnification 60×)Diagnostic Pathology 2006, 1:18 http://www.diagnosticpathology.org/content/1/1/18
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Jones et al [13] also noted that "focal stromal reactions"
were present in the most deeply invasive nests of their
tumors, and around those nests with squamous differen-
tiation. Layton-Henry et al [17] also illustrated in their
report an adenoid basal nest that displayed squamous dif-
ferentiation and an inflammatory stromal reaction. Nests
of ABL should not show necrosis, perineural invasion,
lymphovascular invasion or a significant desmoplastic
reaction [10,20,88]; the presence of one or more of the lat-
ter features should trigger a re-evaluation of a putative
diagnosis.
Adenoid basal lesions associated with separate malignancies
ABL may occasionally be associated with conventional
malignancies within the same specimen. Morphologic
transitions have been identified, albeit inconstantly,
between the pure adenoid basal nests and their associated
malignancies [3]. The latter may also be a focal finding
within an otherwise morphologically pure adenoid basal
lesion [9]. Some authors [9] have interpreted this phe-
nomenon as examples of "divergent epithelial differentia-
tion" in ABL. For the purpose of this review, we would
refer to these as "separate" malignancies. Although this
determination is undoubtedly limited by a selection bias
inherent in the reported cases, ABL appears to be associ-
ated with these separate malignancies at a frequency that
is much higher than would be predicted for high-grade
dysplasia alone. This frequency is also much higher than
would be predicted for any pseudoneoplastic prolifera-
tion of the cervix [90], which some authors have suggested
ABL represents [10,85,88]. The precise frequency with
which ABL is associated with separate malignancies is dif-
ficult to estimate. In their 1971 series of adenoid basal
"lesions", 2 of the 5 cases reported by Baggish and Wood-
ruff were associated with an ACC and an "epidermoid"
carcinoma [23]. The recent study from Parwani et al [3]
perhaps provides the best insight into this issue: these
investigators searched the routine and consultation files
of a large academic center (Baltimore, MD, USA) for the
period between 1984 and 2004. The precise distribution
of consultation versus routine cases was not outlined.
Thirty-three potential cases were identified. The authors
excluded from their study "typical low grade adenoid
basal tumors" (n = 19), which presumably represented
cases unassociated with separate cancers. Of the remain-
ing 14 cases, 10 were retrievable and all were associated
with a carcinoma of non-ABL differentiation. The associ-
ated carcinomas in 8 of the 10 cases were invasive squa-
mous cell carcinomas (1 microinvasive), 1 was a mixture
of SCC and ACC and 1 was a mixture of SCC and small
cell neuroendocrine carcinoma. However, in what
remains the largest series of ABL in the literature, Ferry
and Scully [20], did not identify an associated carcinoma
in 13 of their 14 cases (opinions differ as to whether their
14th case could be considered a true ABL, vide infra). In
the aforementioned study of Parwani et al [3], all 10 cases
showed morphologic transitions between the ABL com-
ponent and the associated conventional malignancy. The
latter were distinguished from the former by virtue of their
greater degree of nuclear atypia, increased mitotic activity
and the presence of a stromal desmoplastic reaction.
However, the invasive component, which as noted previ-
ously was most commonly SCC, also showed various
degrees of "adenoid basal" differentiation ("characterized
by cells in the nests with scanty cytoplasm, peripheral pal-
isading, and focal gland formation") [3].
The relationship between ACC and ABL, separate from
their aforementioned historical co-evolution, is worthy of
mention. These tumors share some morphologic features,
are frequently associated with cervical dysplasia, and both
disproportionately affect the non-white, postmenopausal
population [20]. However, their differences are more sig-
nificant, and the distinction between these 2 neoplasms is
of critical importance given the biologic differences
between them. In contrast to patients with pure ABL, the
majority of ACC patients present with postmenopausal
bleeding and an apparent mass lesion [9,20,21]. Micro-
scopically, the nests of ACC are larger, show necrosis, a
higher mitotic rate and nuclear pleomorphism. ACC is
also typically associated with a significant stromal reac-
tion [9,20,21].
The aforementioned differences notwithstanding, there is
at least a morphologic relationship between ACC and
ABL. Varying amounts of ACC may exist in ABL and vice-
versa [3,9,21,79,82,85,87,89], and morphologic admix-
tures and transitions have been observed between the 2
areas in tumors that are comprised of both. It has been
stated that small ABL-like nests are present in up to 20%
Squamous metaplasia in an adenoid basal nest Figure 8
Squamous metaplasia in an adenoid basal nest. Note the 
basaloid cells at the periphery of the nest. (hematoxylin and 
eosin, original magnification 60×)Diagnostic Pathology 2006, 1:18 http://www.diagnosticpathology.org/content/1/1/18
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of cervical ACC [86,89]. Grayson and colleagues [9] have
championed the viewpoint that ABL and ACC exist along
a morphologic spectrum of basaloid neoplasms of the cer-
vix, and that ABL may even represent a precursor to ACC
(see "histogenesis and pathogenesis" below).
In addition to ACC and SCC, ABL also appears to be asso-
ciated with cervical carcinosarcomas, usually admixed
with an SCC, at a disproportionately high rate given its
overall frequency [5,7,91]. ABL formed a major part of the
epithelial component in 25% of the 8 carcinosarcomas of
the cervix reported by Grayson et al [7]. Similarly, 2 of the
9 cases reported by Clement et al [91] had ABL as an epi-
thelial component, albeit minor. These 2 studies represent
the largest series of cervical carcinosarcomas in the litera-
ture.
Teramoto et al [2] recently reported 7 examples of adenos-
quamous cell carcinoma of the cervix showing ABL-like
areas. Grayson et al [9] had previously reported similar
findings, but with the adenoid basal component predom-
inating. Small ABL-like nests have also been identified
adjacent to cervical basaloid carcinomas, ie squamous cell
carcinomas with basaloid features [10]
We attempted to itemize all cases in the literature in which
an ABL or ABL-like lesion was identified adjacent to a sep-
arate conventional malignancy. Almost 30 cases could be
retrieved [2,3,5,7,9,23,91]. The aforementioned selection
bias notwithstanding, given that only 66 pure ABL have
been reported, this figure appears to be substantial. How-
ever, we emphasize that the precise frequency is not read-
ily quantifiable at present time.
Patient outcomes
Clinicopathologic data for 66 previously reported pure
ABL are summarized in Table 1. The distribution of diag-
nostic and/or therapeutic measures that were adminis-
tered for the 61 patients in which this data was available
and/or sufficiently itemized, was as follows: conization,
loop electrosurgical procedure (LEEP), or cervical excision
alone (n = 11, 18%), conization or LEEP or cervical exci-
sion followed by radiotherapy (n = 2, 3.3%), conization
or LEEP followed by hysterectomy ± unilateral or bilateral
salpingoo-oophorectomy with or without lymph node
sampling (n = 13, 21.3%), hysterectomy ± unilateral or
bilateral salpingoo-oophorectomy alone with or without
lymph node sampling (n = 30, 49.18%, 2 patients in this
group also received chemotherapy that was unrelated to
cervical pathology), hysterectomy ± unilateral or bilateral
salpingoo-oophorectomy and radiotherapy with or with-
out lymph node sampling (n = 3, 5%), Conization, bilat-
eral salpingoo-oophorectomy, lymph node sampling and
radiation (n = 1, 1.6%), dilatation and curettage (n = 1,
1.6%). Follow-up information was available for analysis
in 58 (89%) of the 66 previously reported patients. 3
(5.08%) of these 59 patients died of other causes. Of the
remaining 56 patients, follow-up information was item-
ized on each individual patient in 47 cases. None of these
patients had experienced tumor recurrence, metastases or
tumor-related death, with follow-up periods ranging from
1 to 156 months (mean 44.7; median 28.).
One of the cases reported by Ferry and Scully [20] has gar-
nered a lot of attention as the only example of an alleged
adenoid basal lesion that metastasized and killed the
patient (within 3 months). As the authors themselves
noted, the morphologic features of this tumor differed sig-
nificantly from the others in their series: "the tumor cells
grew slender cords that penetrated deeply into a stroma
showing striking myxoid change, analogous to the mor-
phea type of basal cell carcinoma of the skin" [20]. Hart
[85] has noted that this case was "probably better classi-
fied as a high-grade invasive carcinoma with adenoid
basal-like features". Ferry [88], in an editorial 9 years later,
wrote that "the term ABC, without qualification, should
be used only in cases with typical morphology when the
tumor is composed solely of ABC (with or without associ-
ated squamous dysplasia)". We concur with the latter
statement, and since we do not consider their case 14 [20]
a morphologically pure ABL, it was excluded from our
analysis above and elsewhere in this paper.
In summary, patients that reportedly have been diagnosed
with morphologically pure ABL have had excellent out-
comes, irrespective of the modality of treatment. When
adenoid basal nests are associated with separate conven-
tional malignancies, it can be anticipated that the overall
prognosis will be largely dependent on the stage, grade,
histologic subtype and other clinicopathologic parame-
ters of the associated malignancy.
Histogenesis and pathogenesis
Unfortunately, very little is known about the histogenesis
or pathogenesis of ABL. In their seminal publication, Bag-
gish and Woodruff [24] put forth 2 hypotheses to explain
the histogenesis of ABL. The first was that ABL arose from
the reserve cells – ie indeterminate cells with a capability
for squamous or glandular differentiation – of the cervix.
The second (which the others noted was "highly specula-
tive and unlikely") was that ABL arose from misplaced
ectodermal components in the cervix (i.e ABL was essen-
tially a "variety of a basal cell or appendage lesion"). These
speculations were largely based on vague morphologic
similarities between their cases and adenosquamous cell
carcinoma (for the first hypothesis) and cutaneous basal
cell carcinoma (for the second). Over the ensuing dec-
ades, the latter hypothesis has fallen into disfavor and is
generally not quoted. In contrast, there are several lines of
evidence that suggest that ABL do indeed arise from a cel-Diagnostic Pathology 2006, 1:18 http://www.diagnosticpathology.org/content/1/1/18
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lular population that can show multi-directional differen-
tiation: 1) ABL have been identified in association with
tumors showing glandular, squamous, biphasic epithelial
(adenosquamous) and biphasic epithelial/mesenchymal
(carcinosarcomas) lines of differentiation. 2) ABL tend to
show squamous differentiation (see above) and glandular
structures may be present. 3) Ultrastructurally, the cells of
ABL are rudimentary, with sparse organelles and scattered
intracytoplasmic filaments, and round to oval nuclei with
indentations [6]. The composite of these features, accord-
ing to some authors, causes them to bear a resemblance to
normal cervical reserve cells [6]. Notably, ABL show evi-
dence of both glandular (microvilli) and squamous
(tonofilaments) differentiation even at the ultrastructural
level. [6]. In addition, p63, a marker which preferentially
stains the squamous (and not the glandular) component
of cervical neoplasms [94], shows a marked difference in
staining patterns within individual tumors, with the glan-
dular component showing no or markedly reduced stain-
ing, and the squamous component being strongly positive
[8]. An additional line of evidence that may bolster the
hypothesis of the reserve cell histogenesis is the strong
immunoreactivity for bcl-2 which ABL have shown to
demonstrate [1,6]. The anti-apoptosis gene product, bcl-2
is normally expressed strongly in the basal layer, reserve
cells and immature squamous epithelium of the uterine
cervix [95]. Cviko et al [8] evaluated the proliferative
index (using Ki-67 immunohistochemistry) of 5 ABL, and
noted distinctive patterns of staining that suggested fun-
damental alterations in the cell cycle activity of these
tumors. In the normal squamous epithelium of the cervix,
ki-67 is expressed in the immediate parabasal layer, with
no significant expression in the superficial and intermedi-
ate layers. Cviko et al [8] demonstrated that the "invasive"
nests of ABL, in contrast, showed basaloid cells with vari-
able but generally reduced expression of ki-67, in striking
contrast to the squamous nests at the centers of these nests
which often showed markedly increased proliferative
indices. This was in striking contrast to high grade intraep-
ithelial lesions, in which a basaloid proliferation is typi-
cally associated with a high-proliferative index. The
authors concluded that ABL have a unique pattern of tran-
sitioning morphologic phenotypes associated with
increasing invasion, with the overlying dysplasias show-
ing marked proliferative indices and the deeply invasive
nests showing the opposite.
Jones et al [13] investigated potential roles for the K-ras-2
oncogene and the p53 tumor suppressor gene in the etio-
pathogenesis ABL. None of the 5 cases they evaluated
showed K-ras-2 mutations (exons 1 and 2) in polymerase
chain reaction (PCR)-amplified and sequenced DNA
obtained from selected sites in paraffin embedded tissue
[13]. Weak immunoreactivity for the p53 protein (D0-7
clone) was identified in 4 of 5 cases whereas the expres-
sion was strong and diffuse in the 5th. The latter was
shown to have a missense p53 point mutation (exon 7-
codon 248 tryptophan). [13]. Wild-type p53 induces
WAF-1 expression, thus the authors also investigated the
expression of this protein as an indirect way to assess p53-
related mutational changes. 2 of their 4 cases showing
weak p53 expression were positive for WAF-1, whereas the
5th showing strong p53 expression was negative. Senzaki
et al [11] also demonstrated at the protein level, overex-
pression of p53 protein in an ABL. These alterations in
p53 has been cited by some authors as evidence in sup-
port of the neoplastic nature of ABL [87].
Several studies have demonstrated, utilizing various
modalities, a role for human papillomavirus (HPV) in the
pathogenesis of ABL [1,3,5,7,8,12,13,17]. Using PCR
amplified consensus primers derived from the LI genomic
segment of HPV (primers designed to amplify a large spec-
trum of HPV types), type 16 HPV was identified in 8 of 9
cases in 2 combined studies [8,13]. In another study that
utilized similar methodology [17], HPV was identified in
3 of 5 cases (1 HPV 16, 1 HPV 58 and 1 HPV MM4). Using
a non-isotopic in situ hybridization (NISH) technique
with digoxigenin-labeled probes for HPV types
6,11,16,18,31 and 33, 6 of 9 cases were positive (4 with
HPV 16 and 2 with HPV 33), all notably in a pattern con-
sistent with integration of the HPV genome into the host
cells'[12]. For tumors associated with conventional malig-
nancies, largely similar findings have been reported
[3,5,12]. Parwani et al [3] investigated 10 such tumors
using an in situ hybridization probe for HPV 16, 18 and a
cocktail of different types. HPV type 16 was identified in 9
of 10 cases. PCR analysis of the 10th case showed the pres-
ence of HPV type 33. Notably, both the nests of ABL and
the more conventional malignancies were positive, sug-
gesting a shared histogenetic basis. In those cases in which
ABL were associated with carcinosarcomas, all 3 compo-
nents (pure adenoid basal nests, sarcomatous, carcinoma-
tous) were found to be HPV 16 positive, which further
bolsters the argument of a shared histogenetic basis [5,7].
Immunohistochemical expression of P16, which is gener-
ally considered to be a surrogate marker for high-risk HPV
types [96], was also detected in both the pure adenoid
basal nests and the carcinomatous components in the
study of Parwani et al [3]. Furthermore, as is shown in
Table 1, more than 85% are associated with another HPV-
mediated process, cervical intraepithelial neoplasia.
Although it may be argued that the association is fortui-
tous, the overwhelming predominance of high-grade
lesions (in contrast to low grade lesions which are more
predominant in the general population) suggests a true
biologic relationship, albeit one of an unclear nature. The
complete immunophenotypic profile of the reported ABL
is summarized in table 2.Diagnostic Pathology 2006, 1:18 http://www.diagnosticpathology.org/content/1/1/18
Page 10 of 14
(page number not for citation purposes)
In summary, ABL display a phenotype that most closely
simulates immature squamous cells, squamous basal cells
and/or reserve cells [p63 predominantly positive, prolifer-
ative index variable but generally low, bcl-2 positive]. This
suggests an origination from (or differentiation towards)
a cell that is at an early stage of a differentiation spectrum.
Whether this cell is the reserve cell, remains to be eluci-
dated. p53 alterations and HPV type 16 appear to play sig-
nificant roles in the pathogenesis of these lesions. The
finding of identical HPV types in pure adenoid basal
tumors and their associated conventional malignancies,
as well as the morphologic transitions between them sug-
gests that either 1) pure adenoid basal tumors represent
precursors of their associated malignancies [9] or 2) Both
components are proliferating in response to the same
HPV associated stimulus.
Nomenclature
There has been considerable controversy with respect to
the precise nomenclature applied to ABL, a likely product
of the continued absence of a complete understanding of
their true nature and biologic potential. As noted previ-
ously, the term "adenoid cystic basal carcinoma" was ini-
tially applied by Moss and Collins [82] to describe a
cervical neoplasm that would probably be considered,
using contemporary criteria, a mixed ACC and ABC. The
seminal 1966 report by Baggish and Woodruff [24] was
captioned "adenoid-basal carcinoma of the cervix" and
served to formally introduce the term ABC into the medi-
cal lexicon. However, the 3 lesions were described
throughout the text as "adenoid-basal lesion(s)" and the
authors even stated at the end of their text that "it would
seem wise to apply the term "adenoid-basal cell tumor" to
Table 2: Immunophenotype of Adenoid Basal Lesions.
Antibody Number of cases 
tested
Number positive Percentage 
positive
Morphologic component 
positive
Reference(s)
EMA 14 14 100 Peri-luminary cells 9,20
C D 1 0 111 0 0 A l l 1
ER** 2 1 50 All 1,11
PR** 2 1 50 All 1,11
p 1 6 1 11 11 0 0 A l l 1 , 3
Bcl-2 2 2 100 Basaloid cells and peri-luminary cells 1,6
CEA 17 12 71 Peri-luminary cells and squamous 
areas
1,9,11,14,20
CAM5.2* 9 8 89 All 9
Ki-67 7 7 100 2% positive index [6]; Majority of 
tumor cells positive [11]; 5–50% of 
basaloid cells positive [8]
6,8,11
M N F 1 1 6 991 0 0 A l l 9
CK7 13 7 54 Basaloid cells and peri-luminary cells 2,6,9,11
CK8 4 4 100 Basaloid cells and peri-luminary cells 2,6,11
CK10 1 1 100 Squamous cells 11
CK13 1 1 100 Squamous cells 11
CK14 2 2 100 Basaloid cells [11] and other 
"scattered cells" [6]
6,11
CK17 1 1 100 Basaloid cells 11
CK18 1 1 100 Basaloid cells and periluminary cells 11
CK19 1 1 100 Basaloid cells and peri-luminary cells 11
C K 2 0 911 1 N S 9
AE1/AE3 6 6 100 All 6,20
CK902 5 5 100 All 20
α- S M A 200N A 6 , 1 1
M S A 910T r a n s i t i o n a l  a r e a s  b e t w e e n  a  
combined ABC and ACC
9
Laminin 10 1 10 Basement membrane-like material 6,9
Type IV collagen 10 1 10 Basement membrane-like material 6,9
S100 16 3 19 NS 6,9,11,20
C A 1 2 5 100N A 1 1
P53 6 6 100 NS 11,13
P63 6 6 100 All: reduction of staining in 
squamous areas and "adenoid" areas
1,8
ABC: adenoid basal carcinoma; ACC adenoid cystic carcinoma; ER: estrogen receptor; PR progesterone receptor; CEA carcinoembryonic antigen; 
CK cytokeratin; EMA epithelial membrane antigen; NA not applicable; SMA smooth muscle actin; MSA muscle specific actin; NS not stated.** 
stromal cells only were positive for ER and PR in one case [11].
*Cases reported by Brainard and Hart [10] are excluded because it is not clearly stated how many cases were tested.Diagnostic Pathology 2006, 1:18 http://www.diagnosticpathology.org/content/1/1/18
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this unusual cervical neoplasm" [24]. The term ABC was
only used in the title of their report. In a report of 5 addi-
tional cases in 1971, the aforementioned authors entitled
their report "adenoid basal lesions of the cervix" but this time
used the term ABC in their text to describe not only the
new cases but the cases they previously reported [23].
These 5 cases were comprised in part of 2 cases of ABC
associated with a cylindroma and an epidermoid carci-
noma. The authors designated 2 of the remaining 3 cases
"adenoid basal hyperplasia" whereas the 3rd an ABC. Ade-
noid basal hyperplasia (ABH) was not precisely defined,
and the only clinicopathologic difference between the 2
cases of ABH and the 1 case of ABC appeared to be that the
basaloid proliferation invaded deep into the cervical
stroma in the latter and was superficial in the former. The
term ABH largely remained dormant in the medical liter-
ature until it was resurrected again in a 1985 report of van
Dinh and Woodruff [21]. In that report, the authors noted
that in association with "many" of their cases of ABC were
areas of ABH, "consisting of buds and irregular prolifera-
tions of basal cells attached to the epithelium" and that in
"no case did the basal cell buds extend more than 5 mm
into the stroma" [21]. They further noted that this phe-
nomenon was seen on 11 occasions amongst all the hys-
terectomies that they evaluated over a 12-year period.
Three additional examples of ABH were reported by Brain-
ard and Hart [10] in 1998. The cases of ABH were
described as resembling ABC except that "the epithelial
nests were smaller, and many appeared to remain
attached to the adjacent squamous mucosa or endocervi-
cal clefts". In our opinion, the distinctions that have been
made between ABH and ABC are so nebulous as to be
nearly arbitrary. There are no solid criteria (or a solid basis
for such criteria) for determining at what level of stromal
invasion use of either term would be appropriate. There
are no differences in clinical presentation, patient age, and
certainly biologic behavior between cases of ABC and
ABH [10,23]. We therefore suggest that the term ABH be
discarded altogether. It serves no clinical purpose and
only serves to contribute to the nomenclatural incoher-
ence that has plagued this diagnostic entity.
Given the absence of a single case of tumor recurrence,
metastasis or tumor-related death in an unequivocally
pure ABL, use of the "carcinoma" designation has been
questioned, most forcefully by Brainard and Hart [10,85].
These authors noted that ABL-like lesions showing atypi-
cal histologic features (i.e those associated with a separate
malignancy or having otherwise atypical areas) should
not be considered pure adenoid basal lesions. They pro-
posed the term "adenoid basal epithelioma" (ABE) to
describe cases previously designated ABH and histologi-
cally pure ABC [10]. The term ABE, they argued, "ade-
quately described the composition of epithelial cells and
the mixture of basaloid and glandular elements, but it
avoids designation as carcinoma" [10]. They further
argued that morphologically pure lesions are expected to
have a clinically benign behavior, thus, applying the term
ABE instead of ABC will prevent the potential over-treat-
ment associated with a "carcinoma" diagnosis and is
therefore preferable.
Grayson and Cooper [87,92], in contrast, have argued for
retention of the ABC term for morphologically pure ABT.
These authors argue that the aforementioned integration
of high-risk HPV types [3,12], p53-related genetic changes
[13], and their potential to be the dominant epithelial
component of carcinosarcomas [7,91] are arguments in
support of the neoplastic nature of ABL. In these authors'
opinion, the term ABE "underemphasizes the lesion's
potential for aggressive behavior" [87]. They suggest the
term ABE be used only as a synonym for ABH. The ABC
term continues to be firmly entrenched in the literature
and is used in the most recent classification from the
World Health Organization [93]
Our position on the nomenclature for ABL is closer to the
one proposed by Brainard and Hart [10]. Although we
agree with Grayson and Cooper [87,92] that the presence
of high-risk HPV types in an integrated pattern as well as
p53 changes argues for the neoplastic nature of ABL, it cer-
tainly does not argue for their malignant nature that would
justify use of the term carcinoma. Although pure ABL may
represent precursor lesions to other malignancies, there is
no evidence to suggest that morphologically pure lesions
are, in of themselves, malignant. We know of no other sit-
uation in human oncology in which the term carcinoma
(without an in-situ suffix) is applied for a tumor that has
not been shown to recur, metastasize or cause death. In
our opinion, there is insufficient evidence at present time
to expose patients with morphologically pure ABL to the
ominous implications – social, psychological, medical,
financial – of a "carcinoma" diagnosis. We concur with
use of the designation ABE for morphologically pure ABL.
As noted by Brainard and Hart [10], the term ABE
acknowledges the potentially neoplastic nature of ABT, is
descriptively accurate of their morphology, and most
importantly, avoids use of a term that implies inherent
malignant potential. However, we further recommend
that the term ABE be only used if the entirety of the pro-
liferation is evaluable, e.g in a hysterectomy specimen or
in a cervical excision with negative margins. Given the
aforementioned difficulties in determining the precise fre-
quency with which ABL are associated with separate
malignancies, we suggest use of the simple term "adenoid
basal tumor" for lesions that extend to the margins of an
excisional biopsy or which broadly involves an incisional
biopsy. This may be followed by a comment explaining
this description and stating that the possibility of an asso-
ciated malignancy is probably low but cannot be unequiv-Diagnostic Pathology 2006, 1:18 http://www.diagnosticpathology.org/content/1/1/18
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ocally quantified at present. This allows the patient and
her physician to make an informed decision between a
hysterectomy that eliminates the risk of an unsampled
associated malignancy and retention of the uterus for
reproductive or other purposes. This approach, in our
opinion, strikes an appropriate balance between the need
to prevent over-treatment of pure lesions on one hand,
and the need to ensure that the lesions are indeed pure on
the other. If an ABL is associated with a separate malig-
nancy, then all management options and primary diag-
noses should be based on the stage, grade, histologic
subtype and other clinicopathologic parameters of the
associated malignancy. Using this approach, there is no
use for the term ABC, and we agree with Brainard and Hart
[10] that this designation should no longer be used.
Summary and conclusions
Adenoid basal lesions of the uterine cervix may be associ-
ated, and occasionally show morphologic transitions
with, conventional cervical malignancies, including ade-
noid cystic carcinoma, squamous cell carcinoma
(basaloid and conventional), small cell neuroendocrine
and adenosquamous carcinoma. They may also constitute
the predominant epithelial component of a cervical carci-
nosarcoma. The determination of the precise frequency
with which ABCs show this association is hampered by
the inherent selection bias in the reported cases. However,
this frequency appears to be substantial (>15%). Discus-
sions about ABL should make a clear distinction between
morphologically pure lesions and those associated with
these separate malignancies. The biologic course of ABCs
that are associated with separate malignancies is largely
dependent on the clinicopathologic parameters of the
associated malignancy. Morphologically pure lesions, in
contrast, have a largely benign behavior, and none of the
66 reported patients have experienced tumor recurrence,
metastases or tumor-associated death, irrespective of the
modality of treatment. The finding of morphologic transi-
tions between adenoid basal nests and conventional
malignancies, shared HPV types in these areas, and p53
alterations, all suggest that adenoid basal lesions have
some malignant potential. However, the precise magni-
tude of this potential is not readily quantifiable and
should not dictate the management of morphologically
pure lesions that are entirely evaluable. ABL continue to
occupy a unique position in human oncology in which
the term carcinoma (without an in-situ suffix) is applied
to a tumor that has not been shown to recur, metastasize
or cause death. We concur with a previous proposal that
the terms adenoid basal carcinoma and adenoid basal hyper-
plasia  should be discarded and replaced with Adenoid
Basal Epithelioma (ABE). Even if all related evidence is
interpreted in the most negative light, pure ABL are at
worst, akin to a high grade cervical intraepithelial neo-
plastic lesion in that they may have some potential for
malignant transformation and should be excised. How-
ever, based on the current state of evidence, pure ABL can-
not be considered to be, in of themselves, malignant.
In our opinion, there is insufficient evidence at present
time to expose patients with morphologically pure ade-
noid basal lesions to the ominous implications – social,
psychological, medical, financial – of a "carcinoma" diag-
nosis. The morphologic spectrum of ABL is relatively well-
defined, and any lesion that is not morphologically pure
should not be designated an ABC or ABE. Furthermore,
given the uncertainties regarding the frequency with
which ABE are associated with separate malignancies, we
wish to emphasize that the ABE designation only be
applied when the tumor in question is entirely evaluable,
e.g in a hysterectomy specimen or in an excisional biopsy
with negative margins. Otherwise, the generic designation
adenoid basal tumor is preferable. This approach strikes, in
our opinion, an appropriate balance between the need to
prevent over-treatment of pure lesions on one hand, and
the need to ensure that the lesions are indeed pure on the
other.
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